Article
Author: Prüß, Magdalena ; Schulzke, Jörg-Dieter ; Becker, Christoph ; Romagnani, Chiara ; Sanders, Ashley ; Stoica, Diane ; Radbruch, Andreas ; Voskens, Caroline J. ; Neurath, Markus ; Bacher, Petra ; Chang, Hyun-Dong ; Triantafyllopoulou, Antigoni ; Zundler, Sebastian ; Hildner, Kai ; López-Posadas, Rocío ; Weidinger, Carl ; Bosch-Voskens, Caroline ; Schürmann, Sebastian ; Diefenbach, Andreas ; Hegazy, Ahmed N. ; Müller, Tanja M. ; Trajanoski, Zlatko ; Schumann, Michael ; Scheffold, Alexander ; Wirtz, Stefan ; Berking, Carola ; Liu, Li-Juan ; Atreya, Imke ; Bojarski, Christian ; Siegmund, Britta ; Kummer, Mirko ; Plattner, Christina ; Atreya, Raja ; Stürzl, Michael ; Ronchi, Francesca ; Britzen-Laurent, Nathalie ; Koop, Kristina ; Krug, Susanne ; Wiesinger, Manuel ; Kühl, Anja A. ; Günther, Claudia ; Leppkes, Moritz ; Patankar, Jay V. ; Neurath, Markus F. ; Rosenberg, Marita ; Klose, Christoph S.N. ; Neufert, Clemens ; Waldner, Maximilian ; Ludwig, Leif S.-H.
The imbalance of proinflammatory and antiinflammatory T cells in the gut lamina propria is a hallmark of inflammatory bowel diseases (IBDs) such as Crohn′s disease (CD) and ulcerative colitis (UC).In contrast to other strategies to engineer therapeutic cell products, the approach chosen leads to transient overexpression of GPR15.This seems sufficient, because IMP-Tregs are transferred within 1 h after thawing in our clin. established protocol, and thus, overexpression for up to 24 h leaves substantial time for engineered IMP-Tregs to circulate and finally home to the gut.In conclusion, our data are the first to describe engineered GMP-compliant expanded Tregs with superior gut homing capacity and nominate them for future clin. studies in IBDs.